Details of Disease

General Information of Disease (ID: DISS605N)

Disease Name Her2-receptor negative breast cancer
Disease Hierarchy
DISGN7ZY: Breast carcinoma by gene expression profile
DIS7DPX1: Breast cancer
DISS605N: Her2-receptor negative breast cancer
Disease Identifiers
MONDO ID
MONDO_0000618
UMLS CUI
C4733095
MedGen ID
1684659

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 12 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FGR TTPOGS1 Limited Altered Expression [1]
CA12 TTSYM0R Strong Biomarker [2]
CAPN2 TTG5QB7 Strong Biomarker [3]
CCNE2 TTLDRGX Strong Biomarker [4]
CDK4 TT0PG8F Strong Biomarker [5]
CYP19A1 TTSZLWK Strong Biomarker [6]
EIF2AK4 TT9U4EP Strong Biomarker [7]
FANCF TTNZKFJ Strong Biomarker [8]
KDM5A TTIG67W Strong Biomarker [9]
LIN28A TTO50LN Strong Altered Expression [10]
NECTIN4 TTPO9EG Strong Biomarker [11]
SH3GL1 TTTYNAM Strong Biomarker [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC26A3 DTN1FMD Strong Biomarker [13]
------------------------------------------------------------------------------------
This Disease Is Related to 23 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
DOCK1 OTCFV3ON Limited Altered Expression [14]
NCOA2 OTMQFPBB Limited Altered Expression [1]
GPN3 OTZ4584O moderate Altered Expression [15]
KIF1B OTI1XQTO moderate Biomarker [16]
PCGF2 OTIY1J5L moderate Biomarker [17]
PFKP OTFP7AA8 moderate Biomarker [18]
ADGRF1 OTRAOBYH Strong Altered Expression [19]
ANXA7 OTLMD0TK Strong Biomarker [20]
BTG2 OTZF6K1H Strong Biomarker [21]
FABP7 OTRE2H4G Strong Biomarker [22]
HUNK OTZR4GBH Strong Biomarker [23]
IL2RG OTRZ3OMY Strong Altered Expression [24]
KIF2C OTJ8G3NP Strong Biomarker [25]
KRT16 OTGA0EQN Strong Altered Expression [26]
MAGED2 OTMEWNSE Strong Biomarker [2]
MYBL2 OTZ3JX8Q Strong Biomarker [26]
NPAS2 OTMRT2TS Strong Biomarker [27]
NRF1 OTOXWNV8 Strong Biomarker [28]
NUP43 OTDF5K8Y Strong Altered Expression [29]
SCAMP1 OTFS4IKJ Strong Biomarker [30]
TADA3 OTNUAIO9 Strong Biomarker [31]
TFAP2C OTUDIW05 Strong Biomarker [32]
TRIO OT71X1AK Strong Biomarker [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DOT(s)

References

1 A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells.J Steroid Biochem Mol Biol. 2019 Jan;185:57-70. doi: 10.1016/j.jsbmb.2018.07.011. Epub 2018 Jul 23.
2 Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy.PeerJ. 2019 Sep 3;7:e7515. doi: 10.7717/peerj.7515. eCollection 2019.
3 Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib.Oncotarget. 2018 Sep 7;9(70):33382-33395. doi: 10.18632/oncotarget.26078. eCollection 2018 Sep 7.
4 The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.Sci Rep. 2017 Jan 25;7:41309. doi: 10.1038/srep41309.
5 Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Nave Metastatic Breast Cancer.Clin Cancer Res. 2020 Jan 1;26(1):110-121. doi: 10.1158/1078-0432.CCR-19-0751. Epub 2019 Sep 16.
6 Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.Cancers (Basel). 2019 May 28;11(6):737. doi: 10.3390/cancers11060737.
7 Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism.Am J Cancer Res. 2019 Aug 1;9(8):1766-1775. eCollection 2019.
8 Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis.Front Pharmacol. 2018 Oct 17;9:1184. doi: 10.3389/fphar.2018.01184. eCollection 2018.
9 Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.Oncotarget. 2016 Jun 28;7(26):39931-39944. doi: 10.18632/oncotarget.9539.
10 Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.Breast Cancer Res Treat. 2016 Feb;156(1):135-47. doi: 10.1007/s10549-016-3744-9. Epub 2016 Mar 5.
11 Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer.Pathol Res Pract. 2017 Sep;213(9):1102-1108. doi: 10.1016/j.prp.2017.07.019. Epub 2017 Jul 24.
12 Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Breast Cancer Res. 2017 Oct 3;19(1):110. doi: 10.1186/s13058-017-0900-z.
13 SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.Breast Cancer Res Treat. 2013 Jan;137(1):213-23. doi: 10.1007/s10549-012-2340-x. Epub 2012 Dec 1.
14 Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis.Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7434-9. doi: 10.1073/pnas.1213050110. Epub 2013 Apr 16.
15 Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy Degree.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819870823. doi: 10.1177/1533033819870823.
16 KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer.Hum Cell. 2019 Apr;32(2):172-184. doi: 10.1007/s13577-018-00229-x. Epub 2018 Dec 17.
17 Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
18 Whole genome DNA methylation signature of HER2-positive breast cancer.Epigenetics. 2014 Aug;9(8):1149-62. doi: 10.4161/epi.29632. Epub 2014 Jul 8.
19 GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.
20 ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities.Methods Mol Biol. 2017;1513:23-35. doi: 10.1007/978-1-4939-6539-7_3.
21 Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Cancer Sci. 2014 Jun;105(6):675-82. doi: 10.1111/cas.12410. Epub 2014 May 2.
22 FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.Oncogene. 2019 Sep;38(37):6445-6460. doi: 10.1038/s41388-019-0893-4. Epub 2019 Jul 19.
23 Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.Oncotarget. 2018 Nov 13;9(89):35962-35973. doi: 10.18632/oncotarget.26311. eCollection 2018 Nov 13.
24 Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.PLoS One. 2012;7(6):e39626. doi: 10.1371/journal.pone.0039626. Epub 2012 Jun 21.
25 A multi-layer inference approach to reconstruct condition-specific genes and their regulation.Bioinformatics. 2013 Jun 15;29(12):1541-52. doi: 10.1093/bioinformatics/btt186. Epub 2013 Apr 22.
26 Identification of key candidate genes, pathways and related prognostic values in ER-negative/HER2-negative breast cancer by bioinformatics analysis.J BUON. 2018 Jul-Aug;23(4):891-901.
27 Loss of circadian clock gene expression is associated with tumor progression in breast cancer.Cell Cycle. 2014;13(20):3282-91. doi: 10.4161/15384101.2014.954454.
28 NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
29 High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer.Future Oncol. 2018 Jun;14(15):1431-1442. doi: 10.2217/fon-2017-0690. Epub 2018 Feb 6.
30 MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.
31 Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.Cell Cycle. 2017 Aug 18;16(16):1515-1525. doi: 10.1080/15384101.2017.1339846. Epub 2017 Jul 31.
32 EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Mol Cancer Ther. 2016 Mar;15(3):503-11. doi: 10.1158/1535-7163.MCT-15-0548-T. Epub 2016 Feb 1.
33 Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.Ann Oncol. 2017 Aug 1;28(8):1836-1841. doi: 10.1093/annonc/mdx264.